Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jorge Cortes

Showing results (41-50 of 791) with videos related to

Pageof 80
Sort By:
Expert Opinion on Investigational Drugs|June 14, 2008
Therapeutic options for patients with clonal and idiopathic hypereosinophiaAlfonso Quintás-Cardama, Jorge Cortes
Journal of Hematology & Oncology|November 29, 2013
Optimizing management of ruxolitinib in patients with myelofibrosis: the need for individualized dosingRuben A Mesa, Jorge Cortes
International Journal of Hematology|June 8, 2006
New strategies in chronic myeloid leukemiaHagop M Kantarjian, Jorge Cortes
Future Oncology (London, England)|October 17, 2008
Nilotinib: a phenylamino-pyrimidine derivative with activity against BCR-ABL, KIT and PDGFR kinasesAlfonso Quintás-Cardama, Jorge Cortes
Expert Opinion on Drug Delivery|December 26, 2014
Liposomal delivery of nucleic acid-based anticancer therapeutics: BP-100-1.01Ana Tari Ashizawa, Jorge Cortes
Expert Opinion on Pharmacotherapy|April 2, 2008
Homoharringtonine for the treatment of chronic myelogenous leukemiaAlfonso Quintás-Cardama, Jorge Cortes
Clinical Advances in Hematology & Oncology : H&O|May 27, 2006
Kinase inhibitors in chronic myelogenous leukemiaAlfonso Quintás-Cardama, Jorge Cortes
Hematology/Oncology Clinics of North America|July 24, 2004
Clonal evolution in chronic myelogenous leukemiaJorge Cortes, Michael E O'Dwyer
Drugs of Today (Barcelona, Spain : 1998)|November 8, 2007
Nilotinib therapy in chronic myelogenous leukemiaAlfonso Quintas-Cardama, Jorge Cortes
Current Oncology Reports|August 15, 2009
Chronic myeloid leukemia in the tyrosine kinase inhibitor era: what is the best therapy?Alfonso Quintás-Cardama, Jorge Cortes
Pageof 80

Showing results (41-50 of 791) with videos related to

Sort By:
Pageof 80
Expert Opinion on Investigational Drugs|June 14, 2008
Therapeutic options for patients with clonal and idiopathic hypereosinophiaAlfonso Quintás-Cardama, Jorge Cortes
Journal of Hematology & Oncology|November 29, 2013
Optimizing management of ruxolitinib in patients with myelofibrosis: the need for individualized dosingRuben A Mesa, Jorge Cortes
International Journal of Hematology|June 8, 2006
New strategies in chronic myeloid leukemiaHagop M Kantarjian, Jorge Cortes
Future Oncology (London, England)|October 17, 2008
Nilotinib: a phenylamino-pyrimidine derivative with activity against BCR-ABL, KIT and PDGFR kinasesAlfonso Quintás-Cardama, Jorge Cortes
Expert Opinion on Drug Delivery|December 26, 2014
Liposomal delivery of nucleic acid-based anticancer therapeutics: BP-100-1.01Ana Tari Ashizawa, Jorge Cortes
Expert Opinion on Pharmacotherapy|April 2, 2008
Homoharringtonine for the treatment of chronic myelogenous leukemiaAlfonso Quintás-Cardama, Jorge Cortes
Clinical Advances in Hematology & Oncology : H&O|May 27, 2006
Kinase inhibitors in chronic myelogenous leukemiaAlfonso Quintás-Cardama, Jorge Cortes
Hematology/Oncology Clinics of North America|July 24, 2004
Clonal evolution in chronic myelogenous leukemiaJorge Cortes, Michael E O'Dwyer
Drugs of Today (Barcelona, Spain : 1998)|November 8, 2007
Nilotinib therapy in chronic myelogenous leukemiaAlfonso Quintas-Cardama, Jorge Cortes
Current Oncology Reports|August 15, 2009
Chronic myeloid leukemia in the tyrosine kinase inhibitor era: what is the best therapy?Alfonso Quintás-Cardama, Jorge Cortes
Pageof 80